|Day Low/High||47.51 / 48.70|
|52 Wk Low/High||8.00 / 63.73|
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
You have to dig below the surface and develop a feel for what stocks are leading.
Although Anthem (ANTM) labeled Sarepta's (SRPT) Duchenne muscular drug as 'not medically necessary,' it doesn't mean the insurer won't offer coverage of the treatment, Baird analysts say.
Anthem (ANTM) said today that it doesn't consider Sarepta's (SRPT) Duchenne muscular dystrophy drug to be 'medically necessary,' as it's demonstrated few clinical benefits.
Equities are holding up well, despite concerns that good economic news increases the chances of a rate hike.
SeaDrill's chairman and top shareholder seems willing to lend a hand to keep the company's leverage in check.
Sarepta Therapeutics' (SRPT) multi-country licensing deal with Summit Therapeutics (SMMT) makes the company 'attractive' to potential buyers, RBC says.
Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) signed an exclusive agreement on Tuesday allowing Sarepta to license Summit's DMD drugs in several countries.
Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.
Cramer says Eaton is heading higher and is taking Flex over Brooks Automation.
Next week brings earnings and more on Deutsche Bank, Cramer says.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ("Catabasis"), and Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne...
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
If the market is looking to correct, election worries are a convenient excuse.
Because every stock has a unique personality that requires its own strategy.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.
Relief over the Federal Reserve's slow-and-steady rates plans fueled another day of gains on Thursday.
Stocks rise Thursday as relief over a patient Federal Reserve fuels market gains.
It's challenging to put cash to work but I'll keep digging.
Stock futures move higher on Thursday as relief over a patient Federal Reserve fuels market gains for a second day.
Sarepta (SRPT) disclosed a public offering worth up to $225 million after Wednesday's closing bell.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in...
BioMarin (BMRN) announced today that it would seek further review of a Patent Trial and Appeal Board ruling over Sarepta's (SRPT) Duchenne muscular dystrophy drug.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has...